Abstracts tagged "rheumatoid arthritis (RA) and shared dicision making"

Abstract Number: 2833 • 2019 ACR/ARP Annual Meeting
Shared Decision Making in Routine Clinical Practice: An Assessment of Audio-recorded Consultations with Rheumatoid Arthritis Patients
Elke Mathijssen¹, Johanna Vriezekolk ² and Bart van den Bemt ², ¹Sint Maartenskliniek, Ubbergen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: International guidelines for rheumatoid arthritis (RA) treatment emphasize that all treatment decisions should be made through a shared decision making (SDM) process between clinicians…
Abstract Number: 630 • 2018 ACR/ARHP Annual Meeting
Is Treatment Adherence of RA Patients to Injectable MTX Influenced By Previous MTX Route of Administration?
René-Marc Flipo¹, Eric Senbel², Sonia Tropé³, Elena Zinovieva⁴, Agnès Courbeyrette⁵ and Hélène Herman-Demars⁴, ¹Hôpital Roger Salengro, Lille, France, ²Rheumatology office, Marseille, France, ³149 avenue du Maine, ANDAR, Paris, France, ⁴Medical Department Nordic Pharma, Paris, France, ⁵Medical Departement, Nordic Pharma, Paris, France
Background/Purpose: Previous studies have shown, that switching from oral to subcutaneous (SC) MTX can lead to improved efficacy and bioavailability (especially for doses ≥15mg/wk) as…
Abstract Number: 2368 • 2018 ACR/ARHP Annual Meeting
Patient Preferences for Disease Modifying Anti-Rheumatic Drug Treatment in Rheumatoid Arthritis: A Systematic Review
Caylib Durand¹, Maysoon Eldoma¹, Deborah A. Marshall² and Glen Hazlewood^1,3, ¹Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ²Community Health Sciences, University of Calgary, Calgary, AB, Canada, ³Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, AB, Canada
Background/Purpose: Treatment choices in rheumatoid arthritis (RA) involve trade-offs in risks, benefits and other considerations such as dosing. Understanding patient preferences for these trade-offs is…
Abstract Number: 1255 • 2017 ACR/ARHP Annual Meeting
Using PROs to Guide Patient-Centered Conversations and Care in Inflammatory Arthritis: The Clinician Perspective
Susan J. Bartlett¹, Katherine Clegg Smith², Elaine de Leon², Michelle Jones³, Anna Kristina Gutierrez⁴, Allie Butanis⁵ and Clifton O. Bingham III⁶, ¹Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD, ⁴Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Rheumatology, Johns Hopkins School of Medicine, Baltimore, MD, ⁶Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Although patient-reported outcomes (PROs) are routinely collected for research and quality purposes, they have not been routinely incorporated into the routine care of patients.…
Abstract Number: 2782 • 2017 ACR/ARHP Annual Meeting
Patient Beliefs and Preference to Initiate a Proposed Medication in Rheumatoid Arthritis
Richard W Martin¹, Rohit Nallani², Andrew D Head¹, Aaron T Eggebeen¹, James D Birmingham¹ and Eric T Slavin¹, ¹Medicine, Rheumatology, Michigan State University, College of Human Medicine, Grand Rapids, MI, ²Michigan State University, College of Human Medicine, Grand Rapids, MI
Background/Purpose : Normative economic theory assumes that people making decisions have complete information of the options, rationally weigh the opportunity costs, expected outcomes and optimize…
Abstract Number: 2084 • 2016 ACR/ARHP Annual Meeting
Effects of a Web-Based Patient Decision Aid on Biologics for Rheumatoid Arthritis: A Proof-of-Concept Study
Linda Li¹, Chris Shaw², Diane Lacaille¹, Elaine Yacyshyn³, C. Allyson Jones⁴, Paul Adam⁵, Cheryl Koehn⁶, Alison Hoens⁷, Jasmina Geldman⁸, Charles Goldsmith⁹, Eric C. Sayre⁸ and Nick Bansback¹⁰, ¹Rheumatology, Arthritis Research Canada, Richmond, BC, Canada, ²School of Interactive Arts and Technology, Simon Fraser University, Surrey, BC, Canada, ³University of Alberta, Edmonton, AB, Canada, ⁴Physical Therapy, University of Alberta, Edmonton, AB, Canada, ⁵Mary Pack Arthritis Program, Vancouver, BC, Canada, ⁶Arthritis Consumer Experts, Vancouver, BC, Canada, ⁷Dept of Physical Therapy, University of British Columbia, Vancouver, BC, Canada, ⁸Arthritis Research Canada, Richmond, BC, Canada, ⁹Faculty of Health Sciences, Simon Fraser University, Vancouver, BC, Canada, ¹⁰School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada
Background/Purpose : Under the treat-to-target approach for patients with rheumatoid arthritis (RA), a biologic agent is considered when the target is not met despite trying…
Abstract Number: 2365 • 2014 ACR/ARHP Annual Meeting
Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Rheumatoid Arthritis Therapy with Etanercept
Richard Martin¹, Ryan Enck², Andrew J. Head³, James Birmingham¹ and Aaron T. Eggebeen⁴, ¹Medicine, Rheumatology, Michigan State University, College of Human Medicine, Grand Rapids, MI, ²Michigan State University College of Human Medicine, Grand Rapids, MI, ³Medicine, Rheumatology, College of Human Medicine, Michigan State University, Grand Rapids, MI, ⁴Medicine, Rheumatology, Michigan State University College of Human Medicine, Grand Rapids, MI
Background/Purpose: To evaluate the comparative effects of a pharmaceutical industry decision guide (Pharm Booklet) and International Patient Decision Aids Standard (IPDAS) compliant patient decision aids…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].